Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D F Bajorin

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
Cancer|March 30, 2000
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedulesD F Bajorin, J A McCaffrey, P M Dodd, et al.
Cancer Research|December 1, 1990
Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanomaD F Bajorin, P B Chapman, G Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2008
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207J E Rosenberg, S Halabi, B L Sanford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1995
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVACA S Sarkis, D F Bajorin, V E Reuter, et al.
Cancer Research|October 15, 1992
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expressionR J Motzer, D M Nanus, P O'Moore, et al.
Cancer|September 1, 1995
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinomaT M Law, R J Motzer, M Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancerA D Seidman, H I Scher, J L Gabrilove, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patientsR J Motzer, M Mazumdar, J Sheinfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-upP K Schultz, H W Herr, Z F Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional studyD F Bajorin, M F Sarosdy, D G Pfister, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Cancer|March 30, 2000
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedulesD F Bajorin, J A McCaffrey, P M Dodd, et al.
Cancer Research|December 1, 1990
Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanomaD F Bajorin, P B Chapman, G Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2008
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207J E Rosenberg, S Halabi, B L Sanford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1995
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVACA S Sarkis, D F Bajorin, V E Reuter, et al.
Cancer Research|October 15, 1992
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expressionR J Motzer, D M Nanus, P O'Moore, et al.
Cancer|September 1, 1995
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinomaT M Law, R J Motzer, M Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancerA D Seidman, H I Scher, J L Gabrilove, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patientsR J Motzer, M Mazumdar, J Sheinfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-upP K Schultz, H W Herr, Z F Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional studyD F Bajorin, M F Sarosdy, D G Pfister, et al.
Pageof 10